In 1992, Cobalis acquired the US patent for the use of cyanocobalamin as an effective method of reducing immunoglobulin (IgE) levels in humans. The Company also, in 2001, received patent approval for using cyanocobalamin for the treatment of allergic disease (allergies, asthma, etc.), via a wide variety of delivery mechanisms. The patents on PreHistin™ describe research which demonstrated reductions in allergy symptoms such as sneezing, nasal congestion and runny nose.

Patents

Cobalis’ US Patent #6,255,294 covers patient-friendly ways to treat IgE-mediated allergic diseases, which include seasonal allergies, year-round allergies, food allergies and asthma using various cobalamin analogues, including cyanocobalamin and methylcobalamin.

PreHistin™ is Protected by the Following US and International Patents:

• US Patent #6,255,294 “Cyanocobalamin Treatment in Allergic Disease&lrquo;
• US Patent #5,135,918 “Method for Decreasing Reaginic Antibody Levels&lrquo;
• European Union Patent # EP1128835
• Australian Patent #771728
• Japanese Patent P2002-533399A
• Canadian Patent 2,358,054
• Mexican Patent 2001-006297

Trademarks

The following are claimed trademarks of Cobalis Corp.:

• PreHistin, PreHistin, Pre-Histin
• PreHistamine, Pre-Histamine
• The World’s First PreHistamine, The World’s First Pre-Histamine
• Prevahist
• Alleratin
• Cobalis
• Smart Science

Read SENIOR MANAGEMENT TEAM